SUMMARY
# Normal Aging to Alzheimer's Disease Transition Trigger — Identifying the Critical Switch Point
## Background and Rationale
This longitudinal validation study investigates the critical transition point from normal cognitive aging to Alzheimer's disease (AD) pathogenesis, addressing one of the most fundamental questions in dementia research. The study aims to identify the biological triggers and early molecular events that initiate AD pathological cascades in previously healthy aging brains. The
METHODOLOGY NOTES
**Phase 1: Participant Recruitment and Baseline Assessment (Months 1-6)**
• Recruit 2,000 cognitively normal participants aged 65-85 years through community health centers and memory clinics
• Screen participants using Mini-Mental State Examination (MMSE ≥28), Clinical Dementia Rating (CDR=0), and neuropsychological battery
• Obtain informed consent and collect demographic data, medical history, and APOE genotyping
• Perform baseline assessments: MRI brain imaging, CSF biomarkers (Aβ42, tau, p-tau181), blood-based biomarkers (p-tau217, GFAP, NfL), and comprehensive cognitive testing
• Establish control cohort of 500 participants with stable cognitive function over 2+ years
**Phase 2: Longitudinal Monitoring and Early Detection (Months 7-60)**
• Conduct comprehensive assessments every 6 months including cognitive testing, biomarker sampling, and neuroimaging
• Implement continuous digital cognitive monitoring using smartphone-based assessments weekly
• Track plasma biomarkers monthly (